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information on Avastin’s effectiveness led to greater reliance on the ODAC decision 
by providers. Only one other study has examined the impact of ODAC and our results 
are consistent with their findings. The impact of region on prescribing practices may 
be due to the high concentration of academic medical centers in the North east. The 
FDA needs to fully understand the impact of their advisory bodies on influencing 
providers when considering the public’s health needs.
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Objectives: The treatment landscape for metastatic castrate-resistant prostate 
cancer (mCRPC) has changed following the introduction of new agents abiraterone, 
denosumab and cabazitaxel in 2011, and enzalutamide in 2013. The objective of this 
study was to quantify treatment trends for mCRPC. MethOds: Chart audit data 
from patients with mCRPC was collected quarterly from 2012 to 2014 from a physi-
cian panel of urologists, uro-oncologists and medical oncologists. Data included 
patient demographics, disease characteristics, and treatment details. Treatment 
regimens were categorized into: ADT, new oral agents, or chemotherapy. The use of 
bone-targeted agents (BTAs) was also noted. Results: The percentage of mCRPC 
patients being treated with oral treatments increased from 9% in 2012 to 15% in 
2013 to 61% in 2014 across all lines of treatment. The usage of BTA in order to 
reduce the risk of skeletal related events increased from 61% to 69% to 80% over 
the three years. In addition, patients are initiating treatment with BTA sooner after 
confirmation of bone metastases on bones can. The percentage of patients initiat-
ing treatment upon confirmation of bone metastases increased by 93% from 2012 
to 2014. cOnclusiOns: There has been a strong uptake of new oral agents for the 
treatment of mCRPC. A greater proportion of patients are receiving BTA as compared 
with 2012, and physicians are now less likely to delay initiating BTA treatment.
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ObjectivOs: analizar el comportamiento de pacientes con cáncer de mama a par-
tir de la información de gastos y costos reportada en el 2013 en una aseguradora 
colombiana del régimen contributivo. MetOdOlOgíAs: a partir de la información 
de uso de servicios reportados y consolidados en el año 2013, se desarrolló un 
análisis descriptivo de los pacientes identificados con cáncer de mama afiliados 
a Coomeva-EPS, los pacientes fueron identificados por los diagnósticos según el 
código CIE-10. Se estimó, caracterizó e identificaron los costos de atención de cada 
paciente y sus variaciones por características epidemiológicas, discriminando los 
resultados por departamento. En el análisis solo se incluyen costos reconocidos 
dentro del plan de beneficios colombiano. ResultAdOs: se identificaron 2692 
pacientes únicos con cáncer de mama que correspondería a una prevalencia de 
0,092% del total de afiliados, siendo el 98% mujeres con una edad promedio de 
55 +/-12,7 años. El costo promedio anual por paciente fue de $10.385.724 con var-
iaciones importantes por regiones, siendo la población atendida en Bolívar la de 
mayor costo ($19.408.590). Desde el punto de vista de distribución geográfica la 
mayor cantidad de pacientes se encuentran en Valle del Cauca y Antioquia, pero 
en proporciones similares según la cantidad de población afiliada. Desde el punto 
de vista de intervenciones, el 11,92% recibió tratamiento quirúrgico durante ese 
mismo año. El 49,69% del costo es hospitalario y los medicamentos ambulatorios 
corresponden al 24,32% del total. cOnclusiOnes: el costo promedio por paciente 
con cáncer de mama equivale a 18,25 veces la unidad de pago por captación para el 
año 2013 y su alta prevalencia impacta en los costos, siendo el 2,08% del costo total 
de la prestación en salud para el año y el 46,03% del total de los gastos en cáncer. 
Con este análisis se justifica el diseño de estrategias de gestión específica.
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Objectives: Reimbursement of oncology treatments by Brazilian Public Health 
System (SUS) is controlled by the Authorization for High Complexity Procedures 
(APAC) system. Each treatment line has an APAC code associated with a specific 
reimbursement value that should cover all drug expenses in one month. However, 
with innovation and more expensive drugs that have been launched, these fixed 
values may not be enough to cover drug expenses. In this context, our objec-
tive was to compare costs of recommended treatments with values reimbursed 
by the APAC system. MethOds: We reviewed NCCN (National Comprehensive 
Cancer Network) guidelines for mNSCLC and analyzed recommended chemo-
therapy regimens. Regimens costs were calculated and compared to the APAC 
value for metastatic NSCLC which reimburses only 1,100.00BRL (~343.75USD) 
per month. Drugs maximum sales price for government without taxes were 
used. For the drugs that already have generics, calculations were made in two 
different ways: mean price or the lowest price. The following parameters were 
used to calculate regimens costs by milligrams approach: age 65, weight 70kg, 
and body surface 1,70m2. Results: Ten different regimens are recommended 
for metastatic NSCLC, two target therapies, four bevacizumab and two pem-
etrexed based regimens, and other 3 older regimens. By considering mean 
costs of drugs whose patents expired, the APAC value does nt cover any regi-
men. Costs ranged from 574BRL (~179,30USD) to 14,204BRL (~4,439USD). With 
PCN59
rEal World data oN ColoNy-stimulatiNg faCtors (Csf) iN oNCology: 
PattErNs of usE iN brazil
Goes L1, Feijo L1, Rodrigues N2, Moraes Z2, Bottoni A2
1Evidencias - Kantar Health, Campinas, Brazil, 2Evidências - Kantar Health, Campinas, Brazil
Objectives: Incorrect use of colony stimulating factors (CSF) can add unnecessary 
cost to cancer treatments and adverse events to patients. We conducted an epide-
miological study to assess the correlation between CSF use recommendations issued 
by the Brazilian Regulatory Agency of Health (ANS) and technical recommendations 
stated by international guidelines. We also analyzed the main reasons for not rec-
ommending the use of CSF, in patients during chemotherapy. MethOds: Data on 
patients treated with CSF during 2014 was retrieved from Evidências - Kantar Health 
database of administrative claims, which comprises more than 4 million people and 
46 Private Health Insurance Companies (PHIC) in Brazil. Demographic assessment, 
types of tumor, number of patients, treatment purpose, technical recommenda-
tion, ANS recommendation, reason for not recommending and class of requested 
CSF were assessed. Results: We retrieved 440 CSF requests corresponding to 322 
patients. 188 requests were recommended both technically and by ANS. In 200 
claims, CSF use was not recommended by either guidelines or ANS; and only 30 
claims were in discordance, as CSF use was recommended by guidelines but not 
by ANS. Reasons for technical non-recommendation were: requests for primary 
prophylaxis on chemotherapy regimens with risk of febrile neutropenia below 20% 
and no complicating factors (37.5%), secondary prophylaxis in palliative care set-
ting (26%) or request based on complete blood count (CBC) collected at the nadir 
of chemotherapy. cOnclusiOns: Administrative recommendations from ANS are 
in close agreement with the scientific literature. Nevertheless, despite clear inter-
national guidelines and ANS recommendation, there is still a gap in physicians’ 
knowledge about the correct indications for CSF. Continual medical education on 
this topic should emphasize the following of protocols to ensure proper CSF use.
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intROductiOn: Inequitable access to oncology care between the USA and Brazil is 
frequently attributed to delays in regulatory approval by ANVISA. Objectives: The 
purpose of this research was to estimate the differences in regulatory approval time-
lines between the FDA (USA) and ANVISA (BRA) for oncology therapies, while dis-
tinguishing between delays in manufacturer application submissions and ANVISA 
regulatory processes, to understand how these delays may create inequitable patient 
access to care. MethOds: A basket of twenty-three oncology products approved by 
ANVISA after 2002 were surveyed to evaluate the differences in regulatory submis-
sion and approval dates between the USA and Brazil The ANVISA and FDA regulatory 
approval timelines were calculated by obtaining the difference between submission 
and approval dates of each product’s regulatory applications; comparisons between 
the FDA and ANVISA timelines were drawn by taking the difference in each of the 
regulatory bodies’ average approval time for all products Delays in the manufactur-
ers’ submission for regulatory approval in Brazil were calculated by comparing the 
FDA and ANVISA application submission dates for each product. Results: The 
analysis revealed that on average there was a difference of 8.6 months between 
ANVISA and the FDA’s regulatory approval process, with ANVISA averaging approxi-
mately 449 days and the FDA 186 days from submission of an application to regu-
latory approval On average, between Brazil and the USA, the products surveyed 
demonstrated a delay in the manufacturers’ submission for regulatory approval of 
1.1 years (393 days). cOnclusiOns: The results of this study indicate that there 
are significant differences in the regulatory approval timelines between the FDA 
and ANVISA which raise significant concerns over access to equitable treatment for 
oncology patients in these two countries. Importantly, although delays in ANVISA 
approval are significant, the manufacturer’s submission timing has also consider-
ably contributed to delayed patient access to new oncology therapies in Brazil.
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Objectives: Breast cancer is the second most common cause of cancer-related 
death. Women with metastatic disease have low survival rate due in part to the 
lack of effective treatments. In 2008, the U.S. Food and Drug Administration (FDA) 
granted an accelerated approval of Avastin to treat metastatic breast cancer 
(MBC) in combination with paclitaxel. In July 2010, the Oncologic Drug Advisory 
Committee (ODAC) voted unanimously to withdraw the approval. This decision 
was contested by many including the European Medicine Agency (EMA) and the 
National Comprehensive Cancer Network (NCCN). Despite this disagreement, the 
FDA revoked the approval by the end of 2011. This study examined the impact of 
ODAC’s decision on prescribing practices in 2011. MethOds: Truven MarketScan™ 
claims data from 2006 – 2011 was used as the data source. The sample included 
women ≥ 18 years who received specific chemotherapy agent listed in the NCCN 
treatment guidelines for MBC. A difference-in-difference model compared Avastin 
use before/after the 2010 ODAC decision using colorectal cancer to form the control 
group. Results: Providers were about 41% (p< 0.00) less likely to prescribe Avastin 
after 2010. Region impacted this associated. Prescribers in North central, South 
and West were approximately 3.3 – 10.0% (p< 0.00) more likely to prescribe Avastin 
than prescribers in the Northeast. cOnclusiOns: The magnitude of the utilization 
decrease in 2011 is higher than expected. However, we speculate that conflicting 
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La enfermedad renal crónica (ERC) es una condición de salud pública en aumento 
en Colombia y en el mundo. La intervención temprana de los factores de riesgo dis-
minuye su impacto en la morbilidad, mortalidad y costos de atención.ObjectivOs: 
Evaluar la costo-efectividad de un programa de nefroprotección en una cohorte de 
pacientes con ERC, hipertensión arterial (HTA) y/o diabetes mellitus tipo II (DM), 
afiliados a una aseguradora en salud en Colombia. MetOdOlOgíAs: Se construyó 
un modelo de Markov en MS Excel ® para representar la historia natural de la ERC 
considerando 4 estadios de la enfermedad según su progresión, comparando tres 
alternativas de intervención: atención regular de usuarios sin programa (alternativa 
A), programa de nefroprotección inicial (alternativa B) y programa de nefroprotec-
ción avanzado (alternativa C). Los costos directos fueron incluidos, de acuerdo con 
la información disponible en la aseguradora. La medida de resultado fueron Años 
de vida ajustados por calidad (AVAC) tomados de la literatura. Las probabilidades 
de transición se calcularon a partir del seguimiento de 16.992 pacientes con diag-
nóstico de ERC, HTA y/o DM, mayores de 18 años de edad, en 16 ciudades del país, 
durante los años 2010 a 2013. El horizonte temporal fue la vida. La perspectiva fue 
del tercer pagador. Se realizaron análisis de sensibilidad determinísticos y proba-
bilísticos. ResultAdOs: La alternativa B mostró un comportamiento dominado. 
El análisis de costo-efectividad entre la alternativa A y C muestra un ICER de USD $ 
4.826,51 por AVAC a favor de C. cOnclusiOnes: Dada la disposición a pagar de 1 
PIB per cápita para el país, el programa de nefroprotección avanzado es una opción 
muy costo-efectiva. Esta evaluación puede ayudar a los tomadores de decisiones 
a mejorar la asignación de recursos en países en vías de desarrollo al estimular la 
implementación de estrategias preventivas en patologías crónicas.
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Objectives: ST2 reflects activity of the cardioprotective signal and is a prognostic 
marker in heart failure. The aim is to assess the effectiveness of the ST2 for deter-
mination of the prognosis of patient with heart failure. MethOds: We searched the 
8 Korean databases and overseas databases including Ovid-MEDLINE, Ovid-EMBASE 
and Cochrane Library. A total 365 studies were searched through search strategy and 
total of 19 studies were included in the final assessment by the selection criteria. 
Each of the stages from literature search to application of selection standards and 
extraction of data were carried out independently by 2 researchers. We used tools 
of Scottish Intercollegiate Guidelines Networks(SIGN) for assessment of the qual-
ity of literature. Results: The effectiveness of the ST2 was assessed by means of 
association with prognosis(risk ratio(RR) or odds ratio(OR), accuracy of forecasting 
of the prognosis, stratification of risk), correlation with the comparative test and 
relevance with clinical symptoms. The RR or OR of the death arising from ST2 was 
1.01~4.56, the RR of hospitalization was 1.054~2.4. On the other hand, RR of hospi-
talization of BNP was 1.15~2.0, the RR or OR of death arising from NT pro-BNP was 
0.19~1.241. The sensitivity/specificity of the test was respectively 64~87%/51~82% 
and AUC values were 0.689~0.84. The stratification of risk (NRI values) on the death 
rate were reported to be significant at 9.4 and 9.9 in the 2 papers, respectively, the 
other 1 paper reported stratification of risk of the death rate of 0.049 and stratifica-
tion of risk of hospitalization rate of 0.0638. The correlation coefficients with BNP 
was 0.16~0.409 and with NT pro-BNP was 0.28~0.523. The correlation coefficient with 
the peak VO2was 0.30 and with 6-minute walk distance was 0.22. cOnclusiOns: 
The ST2 is effective in determining the prognosis of patients with heart failure and 
useful in treating heart failure.
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Objectives: We aim to evaluate the efficacy and safety of cerebrolysin in Mexican 
patients with acute severe ischemic stroke (ASIS) and to describe their demo-
graphic and clinical characteristics along with their comorbidities and adverse 
events. MethOds: Open label, one arm, and dose decreasing exploratory study in 
30 consecutive patients from “Unidad Hospitalaria Cruz Verde Dr. Delgadillo Araujo” 
with ASIS starting within 48 hours from the onset of stroke; they received 50 ml of 
intravenous cerebrolysin daily for 10 days followed by 10 days of 30 ml. All patients 
underwent CT scan and were examined using the National Institutes of Health 
Stroke Scale (NIHSS) score and Modified Rankin Scale (≥ to 12 and ≥ 3, respectively) 
score at baseline as well as on day 15 after hospital discharged. Difference between 
measures was evaluated with paired Student’s t statistic. Results: The patients 
mean age was 60.26 ± 11.2 years, 16 (53%) were male and a majority were between 
50-70 years (60%). 19 patients reported at least one physical comorbidity (63.3%), 
the most frequently reported comorbidities were hypertension, diabetes mellitus 
and atrial fibrillation (n= 10, 33%; n= 9, 30%; n= 1, 3% respectively). Pretreatment 
mean score on the NIHSS scale was 20.4, SD 3.9, 95 CI [18.9 - 21.82]; mean Modified 
the approach of the cheapest drug in the market, only three regimens are cov-
ered by the APAC: cisplatin+docetaxel (574BRL~179USD), carboplatin+docetaxel 
(1,002BRL~313USD) and carboplatin+paclitaxel (984BRL~307USD). In addition, 
with the exception of target therapies, all regimens are recommended for 21 
days, being two months of APAC correspondent to 3 cycles. Considering this 
time mismatch, only cisplatin+docetaxel fits the APAC. cOnclusiOns: Our 
analysis indicated that patients may not have access to recommended treat-
ment because the reimbursement system is not updated to the advent of new 
technologies.
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Objectives: To estimate the budgetary impact of the samples produced by the 
Tumor Bank of the ‘Instituto Nacional de Cancerología’ of Mexico in order to 
set a recuperation fee for the samples that provides from the perspective of the 
Health Sector of Mexico. MethOds: The study was an observational, retrospec-
tive review of the direct medical costs (CDMs) of each of the processes involved 
in the cryopreservation of samples collected at the tumor bank, on a per sample 
basis. Including materials, laboratory tests, personnel and administration costs. 
Materials and labor costs were determined from hospital information. Costs were 
determined depending on the sample: plasma, tissue and biopsy and costs were 
calculated depending on the process required to preserve each kind of sample. 
Sensitivity analysis was performed using bootstrap. Results: Recuperation 
costs range from 130 to 155 USD. These costs were considered on a five-year time 
frame for the maintenance per sample, which is the average time a sample is 
kept in the bank. cOnclusiOns: This cost analysis, perceive an adequate recu-
peration fee per sample needed in order to guarantee the correct development of 
the bank.
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ObjetivOs: Analisar a sobrevida específica de cinco anos e fatores associados para 
câncer de boca no Brasil MétOdOs: Trata-se de coorte retrospectiva, cuja fonte de 
dados foi a Base Onco, que realizou o relacionamento probabilístico-determinístico 
de todos os registros de autorização para radioterapia e/ou quimioterapia pelo 
Sistema Único de Saúde, entre 2000 e 2006, gerando-se cadastro único para cada 
paciente. O evento de interesse foi o tempo decorrido entre o diagnóstico do câncer 
de boca e o óbito por este câncer. O Modelo de Regressão de Cox foi utilizado para 
avaliar os fatores individuais associados ao evento de interesse. ResultAdOs: O 
presente estudo incluiu os pacientes diagnosticados entre 2002 e 2003 com câncer 
de boca, exceto lábio, e idade entre 19 e 100 anos (N = 6.180). A taxa de sobre-
vida específica em cinco anos foi de 60%. Foram associados à menor sobrevida 
específica: ter idade > 40 anos; apresentar estádio III ou IV; localização em língua, 
assoalho de boca e base de língua; não realizar tratamento cirúrgico, realizar 
somente quimioterapia ou radioterapia e quimioterapia e residir em determi-
nados estados do Brasil. cOnclusões: Os resultados reforçam a necessidade 
de incluir a avaliação das disparidades dos territórios de planejamento como 
possibilidade para incrementar as ações de saúde e melhorar os indicadores de 
sobrevida
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Objectives: The demographic profile of Puerto Rico is changing; according the 
2000 and 2010 Census of the Population, Puerto Rico has 3810,605 and 3,722,133 
inhabitants, respectively. In this period the population of 65 years or older 
increased from 11.2% to 15%; the median age increased from 33.8 years in 2004 
to 37.0 years in 2010. The extent to which these population changes affect cancer 
mortality is not known. The objective was: to assess the impact of changes in the 
demographic profile of Puerto Rico from 2000 until 2010 on melanoma and lung 
cancer mortality. MethOds: The method of Bashir and Esteve (2000) was applied 
in this study. The baseline group was the year 2000 and the comparison group the 
year 2010. The mortality of these groups was assessed according: population size, 
structure of the population and risk. The population was age adjusted. The mortal-
ity of melanoma and lung cancer is from the National Centre of Health Statistics 
and the population from the Census Bureau (2000, 2010). Results: The net change 
in melanoma mortality was one death; there was an increase of 6 deaths due to 
change in the structure and a decrease of 5 deaths due to change in the size (1) 
and due to risk (4). Net change in lung mortality was 22 deaths; an increase of 
166 deaths due to change in the structure and a decrease of 144 deaths, 14 due to 
change in the size and 130 due to risk. cOnclusiOns: Melanoma and lung can-
cer mortality in Puerto Rico has been affected by the change in the demographic 
profile, resulting in an increase in the number of deaths for these two types of 
cancer. The scope of cancer health services should be evaluated in light of this 
demographic change.
